Oral Switch Noninferior for Low-Risk S. Aureus Bloodstream Infection
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 26, 2024 -- For patients with low-risk Staphylococcus aureus (S. aureus) bloodstream infection, early switch to oral antimicrobial therapy is noninferior to intravenous standard therapy, according to a study published online Jan. 17 in The Lancet Infectious Diseases.
Achim J. Kaasch, M.D., from Otto von Guericke University Magdeburg in Germany, and colleagues conducted an international, open-label, randomized, noninferiority trial conducted in 31 tertiary care hospitals involving patients with low-risk S. aureus bloodstream infection. After five to seven days of intravenous antimicrobial therapy, participants were randomly assigned to oral antimicrobial therapy or to continue intravenous standard therapy (108 and 105, respectively). The composite primary end point was the occurrence of any complication related to S. aureus bloodstream infection within 90 days.
The researchers found that the primary end point was met by 13 and 12 percent of participants in the oral switch and intravenous groups, with a treatment difference of 0.7 percentage points (95 percent confidence interval, −7.8 to 9.1; P = 0.013, which met noninferiority). Within the safety population, 34 and 26 percent of participants in the oral switch and intravenous groups, respectively, had at least one serious adverse event.
"This study supports an early switch to oral antimicrobial therapy in patients with low-risk S. aureus bloodstream infection provided a rigorous clinical assessment and close monitoring for complications are done," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Prolonged β-Lactam Antibiotic Infusions Aid Sepsis, Septic Shock Outcomes
FRIDAY, June 14, 2024 -- Among adults in the intensive care unit with sepsis or septic shock, the use of prolonged β-lactam antibiotic infusions is associated with lower risk...
Considerable Variation Seen in Mortality Rates for Suspected Sepsis
TUESDAY, May 28, 2024 -- There is considerable variation in mortality rates among patients with suspected sepsis, according to a research letter published online May 28 in the...
Acetaminophen Does Not Improve Survival in Adults With Sepsis
MONDAY, May 20, 2024 -- For adults with sepsis, intravenous acetaminophen is safe but does not significantly improve the number of days alive and free of organ support, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.